bitolterol (tornalate) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Bitolterol is a beta 2-adrenergic agonist. Since it in itself is biologically inactive, bitolterol is considered a pro-drug. When administered it is activated within the lung by esterase hydrolysis to the active compound colterol catecholamine N-t-butyl-arterenol. Bitolterol was marked under the name tornalate and was indicated to prevent and treat of reversible bronchospasm associated with asthma or chronic obstructive pulmonary diseases. But that drug was withdrawn from the market by Elan Pharmaceuticals in 2001.   NCATS

Chemistry

  • SMILES: Cc1ccc(cc1)C(=O)Oc2ccc(cc2OC(=O)c3ccc(C)cc3)C(O)CNC(C)(C)C
  • InChIKey: FZGVEKPRDOIXJY-UHFFFAOYSA-N
  • Mol. Mass: 461.56
  • ALogP: 5.16
  • ChEMBL Molecules:
    bitolterol  
    bitolterol mesylate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Topical
  • Pro Drug: Yes

Alternative names

bitolterol | bitolterol mesilate | bitolterol mesylate | bitolterol methanesulfonate | bitolterolum | dura brand of bitolterol methanesulfonate | s-1540 | tomalate | tornalate | win 32784 | win-32784

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (2)


 

Asthma (approved 1984)

Pulmonary Disease, Chronic Obstructive (approved 1984)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue